Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trial Examining Methods for Antidepressant Discontinuation (TEMPO)
2024-511997-66-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of paroxetine and venlafaxine in major depressive disorder (MDD), sponsored by Amsterdam University Medical Center. Primary endpoint: Rate of failure to successfully discontinue antidepressant. Planned start Nov 2024; status: authorised.
02
Drugs
paroxetinevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-511997-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511997-66-00.